TetraLogic Pharmaceuticals, Inc.: Series C $32M

Posted in I - Series C, Q - 3Q10, R - NORTH EAST, X - Apoptosis, X - Necrosis, XX - PA

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Jul

2010

FerroKin Biosciences, Inc.: Series B $12M

Posted in I - Series B, Q - 2Q10, R - WEST, X - Anemia, XX - CA

FerroKin Biosciences (San Carlos, CA) a preclinical-stage biopharmaceutical company focused on iron chelator for treatment of anemia, closed a $12M Series B financing. Participants include Clarus Ventures, Burrill & Co., Celegene, MP Healthcare Venture Management and Healthcap Ventures.

May

2010

Oxford Immunotec, Ltd.: Series D $26M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Device (Diagnostic), X - Tuberculosis

Oxford Immunotec (United Kingdom) a commercial-stage molecular diagnostic company focused on an vitro test for the diagnosis of active and latent tuberculosis infection, closed a $26M Series D financing. Participants include New Leaf Venture Partners, Kaiser Permanente Ventures, Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Spark Ventures, DFJ Esprit, Oxford University and Dow Chemical.

Apr

2010

Catabasis Pharmaceuticals, Inc.: Series A $39.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Inflammation, X - Metabolism, XX - MA

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Mar

2010

Pearl Therapeutics, Inc.: Series C $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Neomend, Inc.: Series D $30M

Posted in I - Series D, Q - 1Q10, R - WEST, X - Wound Healing, XX - CA

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

Feb

2010

Zogenix, Inc.: Series B $20M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Feb

2010

Ophthotech Corp.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...